Quantcast

Latest Rhinitis Stories

2008-11-06 11:17:34

LONDON and NEW YORK, Nov. 6 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, today announced positive data from its ICH compliant Phase II equivalent multi-center study of MRX-4 (n=105) in patients suffering from allergic rhinitis. MRX-4 was given as an intranasal spray formulation. The Nasal Allergen Challenge (NAC) study was conducted in allergic rhinitis patients outside of the local allergy season. MRX-4 was compared...

2008-11-05 09:00:34

WALTHAM, Mass., Nov. 5 /PRNewswire/ -- Decision Resources one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that physicians and patients respond to different marketing messages when considering which asthma medicine to use. Physicians indicate that brands conveying messages of improvements in patient-centered outcomes such as number of symptom-free days, reduction in acute exacerbations and quality of life receive more positive...

2008-10-30 12:00:21

Morria Biopharmaceuticals, a developer of novel, anti-inflammatory drugs, has announced the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort as the steroid comparator arm. A secondary efficacy endpoint of this study was the effect of MRX-4 on inflammatory mediators or markers in the...

2008-10-29 12:00:07

LONDON, Oct. 29 /PRNewswire/ -- Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on the development of novel, anti-inflammatory drugs, announced today the preliminary results from its recently completed Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis (AR). The two-arm, randomized, multi-dose, double-blind, placebo-controlled study included Rhinocort(R) as the steroid comparator arm. A secondary efficacy...

2008-10-28 06:00:28

Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation. Anders Lonner, CEO of Meda, said: "This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute...

2008-10-27 15:00:00

ANTONY, France, October 27 /PRNewswire-FirstCall/ -- Stallergenes has just obtained authorization (IND(1)) from the FDA for immediately launching a phase III clinical trial in the United States with Oralair(R) Grasses in the treatment of allergic rhinoconjunctivitis to grass pollens in adults. The aim of the study, which will be conducted in 450 American patients during the 2009 pollen season, is to confirm the efficacy and good tolerance of the product in adults and to support the...

2008-10-17 03:00:16

Regulatory News: Meda AB (STO:MEDAA): The U.S. Food and Drug Administration (FDA) has approved Astepro - the new formulation of Astelin. Astepro Nasal Spray is an improvement over the marketed Astelin Nasal Spray and is better tolerated by patients using the new spray. The active substance in these products is azelastine - the leading nasal antihistamine in the treatment of rhinitis in the U.S. Astepro is now approved for treatment of seasonal allergic rhinitis. Fewer reports...

2008-10-06 21:00:11

Thai researchers suggest patients on allergy medicine are better served when they adjust their dose to symptoms. The researchers found the effectiveness of intranasal corticosteroids -- a drug that reduces swelling and secretions in the nose -- could be achieved with three-quarters of the usually recommended daily dosage when patients were instructed how to vary the daily dosage in response to severity of symptoms. This new approach to dosing could help prevent the problem of increased...

2008-10-03 09:00:38

Circassia, a specialty biopharmaceutical company, has started a further Phase II clinical study of its ToleroMune technology in the field of cat allergy. The trial builds on positive results achieved in an earlier Phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous Phase II clinical trial, patients experienced substantially reduced reactions to cat allergens after a single administration of ToleroMune...

2008-10-02 06:00:34

OXFORD, England, October 2 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on the fields of allergy and critical care, today announced the start of a further phase II clinical study of its ToleroMune(R) technology in the field of cat allergy. The trial builds on positive results achieved in an earlier phase II study, which demonstrated the potential clinical benefits of the ToleroMune approach to allergy desensitization. In the previous phase II clinical trial,...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related